ClinicalTrials.gg
RecruitingNCT07702149Updated Jul 14, 2026

Diet Restiction in Subjects With Behcet Disease and Complaint of Tinnitus

An interventional study of diet restriction in Behcet Disease, Obesity and Subjective Tinnitus, sponsored by Cairo University. Recruiting at 2 sites in Egypt. Open to participants aged 40 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 55 Years
Sex
All
01

Study summary

otogic problems are varied in bechet disorder, tinnnitus is one of these problems. obesity may increase this probelm

Read the detailed description

Forty subjects with behcet disorder, excess weight, complaint o tinnnitus will divided to group I or group II. low caorie diet 12-week regeim wil be followed by 20-patient group I . the 20-patient group II will be waitlist.

02

Conditions studied

  • Behcet Disease
  • Obesity
  • Subjective Tinnitus
03

In context

Behcet Syndrome

136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.

This study's planned enrollment of 40 is below the median of 50 across 70 interventional studies indexed under Behcet Syndrome.

Browse Behcet Syndrome studies →

Lead sponsor

Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • behcet disease
  • obesity
  • subjective tinnitus (bilateral)

Exclusion criteria

Exclusion Criteria:

  • other autoimune diseases
  • refusal to participate
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    group number 1

    twenty subjects with behcet disorder, excess weight, complaint o tinnnitus will follow low caorie diet 12-week regeim

    Behavioral: diet restriction

  • No intervention
    group number 2

    twenty subjects with behcet disorder, excess weight, complaint o tinnnitus will will be waitlist without intervention

Interventions

  • Behavioraldiet restriction

    twenty subjects with behcet disorder, excess weight, complaint o tinnnitus will follow low calorie diet 12-week regeim.

06

What researchers measure

Primary outcomes

  1. tinnitus handicap inventory

    it will assess life quality

    Time frame: it will be measured after 12 weeks

Secondary outcomes

  1. visual analog scale of severity of complint of tinnitus

    it will assess severity of complint of tinnitus

    Time frame: It will be measured after 12 weeks

  2. visual analog scale of discomfort induced by complint of tinnitus

    it will assess discomfort induced by complint of tinnitus

    Time frame: It will be measured after 12 weeks

  3. tinnitus reaction scale

    it assess psychaological stressful satus

    Time frame: It will be measured after 12 weeks

  4. waist circumfereence

    it will be assessed at level of umbilicus

    Time frame: it will be measured after 12 weeks

  5. body mass index

    it will be assessed on empty bladder and bowel

    Time frame: It will be measured after 12 weeks

  6. sate trait anxiety inventory

    questionnaire will assess anxiety

    Time frame: It will be measured after 12 weeks

  7. beck depression scale

    it wil assess depression level

    Time frame: It will be measured after 12 weeks

  8. satifiaction with life scale

    it will assess level of satisfaction with life

    Time frame: It will be measured after 12 weeks

  9. behcet diseae life quality scale

    it will assess life quality in relation to behcet disease

    Time frame: It will be measured after 12 weeks

  10. insomnia severity index

    questioanire will assess sleep quality

    Time frame: It will be measured after 12 weeks

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Sep 2026, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 14, 2026
StartActual
Jun 4, 2026
Primary completionEst.
Sep 10, 2026
CompletionEst.
Sep 10, 2026
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07702149
Lead sponsor
Cairo University
Responsible party
Ali Mohamed Ali ismail (lecturer of physical therapy for Cardiovascular, Respiratory disorder and Geriatrics, Faculty of Physical Therapy, Cairo University, Cairo University) — Principal investigator
First posted
Jul 14, 2026
Start date
Jun 4, 2026
Primary completion
Sep 10, 2026 (estimated)
Completion
Sep 10, 2026 (estimated)
Last update
Jul 14, 2026

Study contacts

Ali MA Ismail, lecturer
Contact
ali.mohamed@pt.cu.edu.eg
01005154209
Ali mohamed, lecturer
Contact
fatmaraed1994@gmail.com
0201031321109
Ali MA Ismail, lecturer
principal investigator · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion